Biovest One Step Closer to Cancer Vaccine Approval in Europe

biovaxid-logo.jpg

Biovest International, the biopharmaceutical company behind BiovaxID, a personalized therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma, has taken another step closer to European marketing approval following a regulatory meeting with the European Medicines Agency (EMA)

At the meeting, the EMA provided Biovest with guidance along with legal, regulatory, and scientific information to help finalize their pending Marketing Authorization Application (MAA) seeking EU marketing approval for BiovaxID.

While no time frame can be determined with regard to availability in Europe, if approved it will be the first therapeutic cancer vaccine designed for patients with non-Hodgkin's lymphoma.

Additionally, Biovest has appointed David J. States, M.D., Ph.D., to the their Scientific Advisory Board. Educated at Harvard, at the University of California, San Diego and the National Institutes of Health, Dr. States is a systems biologist who helped to established the discipline of bioinformatics. He is board certified in internal medicine and is a Fellow of the American College of Medical Informatics. Dr. States has been involved in the Human Genome Project from the outset of the project and helped to establish the NIH National Center for Biotechnology Information (NCBI).

Source: Biovest

LymphomaInfo Social